Puma Biotechnology reports Q1 EPS 10c, two estimates 3c
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2025
0mins
Should l Buy PBYI?
Q1 Financial Performance: The company reported a Q1 revenue of $43.1 million, slightly below estimates of $44.5 million, but achieved better than expected net income according to CEO Alan H. Auerbach.
Clinical Trials Updates: New clinical data on neratinib was presented at the AACR Annual Meeting 2025, with key milestones anticipated in the next year for ongoing alisertib studies, including interim data presentations for breast and lung cancer trials scheduled for H2 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBYI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBYI
Wall Street analysts forecast PBYI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBYI is 3.50 USD with a low forecast of 2.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 6.790
Low
2.00
Averages
3.50
High
5.00
Current: 6.790
Low
2.00
Averages
3.50
High
5.00
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Puma Biotechnology Grants Stock Awards to New Employees
- Stock Award Program: On February 3, 2026, Puma Biotechnology approved the grant of 14,750 restricted stock units to two new non-executive employees, aimed at attracting talent and enhancing employee loyalty.
- Vesting Conditions: Under the 2017 Employment Inducement Incentive Award Plan, the stock units will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter, ensuring continued employee service.
- Product Development Progress: Puma focuses on developing innovative cancer treatment products, having received FDA approval for neratinib in 2017, which further solidifies its market position in breast cancer treatment.
- Clinical Trial Initiation: In 2024, Puma initiated the ALISCA™-Lung1 Phase II clinical trial for small cell lung cancer, demonstrating the company's ongoing efforts and market potential in cancer drug development.
See More
EU and India Reach Landmark Trade Agreement
- Trade Agreement Reached: Indian Prime Minister Modi announced a free trade agreement with the EU, dubbed the 'mother of all deals,' covering 25% of global GDP and a third of global trade, which is expected to significantly enhance economic cooperation and market access between the two regions.
- Positive Market Reaction: European stocks broadly rose, with the pan-European Stoxx 600 index up 0.3%, reflecting investor optimism regarding the new trade agreement while preparing for an influx of corporate earnings reports.
- Significant Industry Impact: The EU's major exports to India include machinery, transport equipment, and chemicals, while India's key exports to the EU are also machinery, chemicals, and fuels, indicating a complementary relationship that will foster collaboration and growth across multiple sectors.
- Earnings Season Kicks Off: As the earnings season begins, investors are keenly watching financial reports from ASML, Volvo, LVMH, and Deutsche Bank, with market sentiment appearing more positive in light of the new trade agreement.
See More
Puma Biotechnology Grants 10,500 Restricted Stock Units to New Employees
- Employee Incentive Program: On January 6, 2026, Puma Biotechnology approved the grant of 10,500 restricted stock units to three new non-executive employees, aimed at attracting and retaining talent to enhance the company's competitiveness.
- Stock Vesting Arrangement: The stock units will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter, ensuring continued service and alignment with company growth.
- Compliance Assurance: This stock grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating Puma's commitment to transparency and compliance in attracting new employees, which bolsters investor confidence.
- Support for R&D Investments: Puma's focus on innovative cancer treatment products will benefit from this incentive, helping to attract key talent to advance R&D projects, including the new drug alisertib, thereby enhancing market competitiveness.
See More
Puma Biotechnology Added to Nasdaq Biotechnology Index, Enhancing Visibility
- Nasdaq Recognition: Puma Biotechnology is officially added to the Nasdaq Biotechnology Index effective December 19, 2025, marking a significant acknowledgment of the company's ongoing commercial execution, profitability, and clinical progress, thereby enhancing its visibility within the biotechnology investment community.
- Sustained Product Demand: With continued demand for NERLYNX® and advancements in the development of alisertib, Puma's CEO stated that this milestone will help create greater value for patients and shareholders, further solidifying the company's market position.
- Clinical Trial Advancement: In February 2024, Puma initiated the ALISCA™-Lung1 clinical trial focusing on alisertib monotherapy for patients with extensive-stage small cell lung cancer, demonstrating the company's commitment to research and development in cancer treatment.
- Market Entry Standards: Companies in the Nasdaq Biotechnology Index must meet various criteria, including minimum market capitalization and average daily trading volume, and Puma's inclusion reflects its maturity as a public company and market recognition.
See More
Puma Biotechnology Grants 3,500 Restricted Stock Units to New Employee
- Stock Award Plan: On December 1, 2025, Puma Biotechnology approved the grant of 3,500 restricted stock units to a new non-executive employee, aimed at attracting talent and enhancing employee loyalty.
- Vesting Conditions: The stock units will vest over three years, with one-third unlocking in the first year and one-sixth every six months thereafter, ensuring continued service for full benefits.
- Incentive Mechanism: This award is granted under Puma's 2017 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4), designed to attract and retain key talent through equity incentives.
- Corporate Strategy: By implementing such incentive measures, Puma not only boosts employee motivation but also strengthens its market position in the highly competitive biopharmaceutical industry.
See More
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Superior Choice?
Ironwood Pharmaceuticals Overview: Ironwood focuses on gastrointestinal disorders with its sole marketed drug, Linzess, which has seen significant sales growth, leading to an optimistic revenue outlook for 2025. The company is also developing apraglutide for short bowel syndrome, although it remains heavily reliant on Linzess for revenue.
Puma Biotechnology Overview: Puma Biotechnology specializes in cancer treatments, particularly with its drug Nerlynx for breast cancer, which has shown modest sales growth. However, the company faces risks due to its dependence on a single product and competition in the crowded breast cancer market.
Investment Comparison: Analysts suggest that Ironwood may be a better investment opportunity compared to Puma Biotechnology, given its steady earnings momentum and positive growth outlook, despite Ironwood's higher price-to-sales ratio.
Market Performance: Year-to-date, Ironwood's shares have declined while Puma's have surged, reflecting differing market perceptions. Ironwood's strong revenue guidance and rising earnings estimates contrast with Puma's vulnerability to regulatory and competitive challenges.
See More
Puma Biotechnology Grants Stock Awards to New Employees
- Stock Award Program: On February 3, 2026, Puma Biotechnology approved the grant of 14,750 restricted stock units to two new non-executive employees, aimed at attracting talent and enhancing employee loyalty.
- Vesting Conditions: Under the 2017 Employment Inducement Incentive Award Plan, the stock units will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter, ensuring continued employee service.
- Product Development Progress: Puma focuses on developing innovative cancer treatment products, having received FDA approval for neratinib in 2017, which further solidifies its market position in breast cancer treatment.
- Clinical Trial Initiation: In 2024, Puma initiated the ALISCA™-Lung1 Phase II clinical trial for small cell lung cancer, demonstrating the company's ongoing efforts and market potential in cancer drug development.
See More
EU and India Reach Landmark Trade Agreement
- Trade Agreement Reached: Indian Prime Minister Modi announced a free trade agreement with the EU, dubbed the 'mother of all deals,' covering 25% of global GDP and a third of global trade, which is expected to significantly enhance economic cooperation and market access between the two regions.
- Positive Market Reaction: European stocks broadly rose, with the pan-European Stoxx 600 index up 0.3%, reflecting investor optimism regarding the new trade agreement while preparing for an influx of corporate earnings reports.
- Significant Industry Impact: The EU's major exports to India include machinery, transport equipment, and chemicals, while India's key exports to the EU are also machinery, chemicals, and fuels, indicating a complementary relationship that will foster collaboration and growth across multiple sectors.
- Earnings Season Kicks Off: As the earnings season begins, investors are keenly watching financial reports from ASML, Volvo, LVMH, and Deutsche Bank, with market sentiment appearing more positive in light of the new trade agreement.
See More
Puma Biotechnology Grants 10,500 Restricted Stock Units to New Employees
- Employee Incentive Program: On January 6, 2026, Puma Biotechnology approved the grant of 10,500 restricted stock units to three new non-executive employees, aimed at attracting and retaining talent to enhance the company's competitiveness.
- Stock Vesting Arrangement: The stock units will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter, ensuring continued service and alignment with company growth.
- Compliance Assurance: This stock grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating Puma's commitment to transparency and compliance in attracting new employees, which bolsters investor confidence.
- Support for R&D Investments: Puma's focus on innovative cancer treatment products will benefit from this incentive, helping to attract key talent to advance R&D projects, including the new drug alisertib, thereby enhancing market competitiveness.
See More
Puma Biotechnology Added to Nasdaq Biotechnology Index, Enhancing Visibility
- Nasdaq Recognition: Puma Biotechnology is officially added to the Nasdaq Biotechnology Index effective December 19, 2025, marking a significant acknowledgment of the company's ongoing commercial execution, profitability, and clinical progress, thereby enhancing its visibility within the biotechnology investment community.
- Sustained Product Demand: With continued demand for NERLYNX® and advancements in the development of alisertib, Puma's CEO stated that this milestone will help create greater value for patients and shareholders, further solidifying the company's market position.
- Clinical Trial Advancement: In February 2024, Puma initiated the ALISCA™-Lung1 clinical trial focusing on alisertib monotherapy for patients with extensive-stage small cell lung cancer, demonstrating the company's commitment to research and development in cancer treatment.
- Market Entry Standards: Companies in the Nasdaq Biotechnology Index must meet various criteria, including minimum market capitalization and average daily trading volume, and Puma's inclusion reflects its maturity as a public company and market recognition.
See More
Puma Biotechnology Grants 3,500 Restricted Stock Units to New Employee
- Stock Award Plan: On December 1, 2025, Puma Biotechnology approved the grant of 3,500 restricted stock units to a new non-executive employee, aimed at attracting talent and enhancing employee loyalty.
- Vesting Conditions: The stock units will vest over three years, with one-third unlocking in the first year and one-sixth every six months thereafter, ensuring continued service for full benefits.
- Incentive Mechanism: This award is granted under Puma's 2017 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4), designed to attract and retain key talent through equity incentives.
- Corporate Strategy: By implementing such incentive measures, Puma not only boosts employee motivation but also strengthens its market position in the highly competitive biopharmaceutical industry.
See More
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Superior Choice?
Ironwood Pharmaceuticals Overview: Ironwood focuses on gastrointestinal disorders with its sole marketed drug, Linzess, which has seen significant sales growth, leading to an optimistic revenue outlook for 2025. The company is also developing apraglutide for short bowel syndrome, although it remains heavily reliant on Linzess for revenue.
Puma Biotechnology Overview: Puma Biotechnology specializes in cancer treatments, particularly with its drug Nerlynx for breast cancer, which has shown modest sales growth. However, the company faces risks due to its dependence on a single product and competition in the crowded breast cancer market.
Investment Comparison: Analysts suggest that Ironwood may be a better investment opportunity compared to Puma Biotechnology, given its steady earnings momentum and positive growth outlook, despite Ironwood's higher price-to-sales ratio.
Market Performance: Year-to-date, Ironwood's shares have declined while Puma's have surged, reflecting differing market perceptions. Ironwood's strong revenue guidance and rising earnings estimates contrast with Puma's vulnerability to regulatory and competitive challenges.
See More
